InSphero provides superior biological relevance to in vitro testing with easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. Our patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumor tissues. These models help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. Microtissues are available directly or through a menu of 3D InSight™ Standard Services, supported by a comprehensive panel of 3D-optimized culture media, assay protocols, and imaging solutions. InSphero’s technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HTS-DILI, and validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer. Founded in 2009 and privately held, InSphero is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.